Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-Current Deffered Revenue: 2015-2018

Historic Non-Current Deffered Revenue for Viking Therapeutics (VKTX) over the last 1 years, with Dec 2018 value amounting to $12,000.

  • Viking Therapeutics' Non-Current Deffered Revenue was N/A to $12,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $12,000, marking a year-over-year change of. This contributed to the annual value of $12,000 for FY2018, which is N/A change from last year.
  • According to the latest figures from Q4 2018, Viking Therapeutics' Non-Current Deffered Revenue is $12,000, which was up 98.22% from $6,054 recorded in Q2 2017.
  • In the past 5 years, Viking Therapeutics' Non-Current Deffered Revenue registered a high of $31,239 during Q4 2015, and its lowest value of $6,054 during Q2 2017.
  • In the last 3 years, Viking Therapeutics' Non-Current Deffered Revenue had a median value of $16,307 in 2016 and averaged $16,853.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first increased by 6.93% in 2016, then crashed by 75.44% in 2017.
  • Over the past 4 years, Viking Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $31,239 in 2015, then plummeted by 47.80% to $16,307 in 2016, then plummeted by 75.44% to $6,054 in 2017, then reached $12,000 in 2018.
  • Its Non-Current Deffered Revenue stands at $12,000 for Q4 2018, versus $6,054 for Q2 2017 and $10,862 for Q1 2017.